Successful treatment of refractory pruritic Fox-Fordyce disease with botulinum toxin type A

González-Ramos, J.; Alonso‐Pacheco, M.L.; Goiburú-Chenú, B.; Mayor-Ibarguren, Ander; Pinto, Pedro Herranz

doi:10.1111/bjd.14180

Cited by 20 publications

(17 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, some tentative treatments of varying efficacy have been reported in recalcitrant FFD cases. They include oral contraceptives, botulinum toxin, oral retinoids, surgical removal, carbon dioxide lattice laser, pulsed dye laser, phototherapy, microwave technology, and electrocoagulation (Ahmed Al‐Qarqaz & Al‐Shannag, ; Gonzalez‐Ramos, Alonso‐Pacheco, Goiburu‐Chenu, Mayor‐Ibarguren, & Herranz‐Pinto, ; Han, Lee, & Rhie, ; Taylor, ; Uzuncakmak et al, ). No single treatment, however, has proved curative.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Rapid remission with calcipotriol betamethasone in refractory Fox–Fordyce disease

Yang

Zhang

Wang

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Fox–Fordyce disease (FFD) is a rare pruritic dermatosis whose etiology has not been fully explored. It is mostly seen in women and presents as pruritic follicular papules at the apocrine (gland‐bearing) regions, including the axilla, groins, perineum, and areola mammae, as well as the umbilicus. Treatment for FFD is extremely challenging in that there is no curative treatment for it. We report the case of a 26‐year‐old woman who was refractory to many treatments but who responded to calcipotriol betamethasone with rapid remission of her symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

“…We present a patient diagnosed with FFD who responded to calcipotriol betamethasone with rapid remission of her symptoms. Pinto, 2016;Han, Lee, & Rhie, 2016;Taylor, 2016;Uzuncakmak et al, 2016). No single treatment, however, has proved curative.…”

Section: Introductionmentioning

confidence: 99%

Rapid remission with calcipotriol betamethasone in refractory Fox–Fordyce disease

Yang

Zhang

Wang

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…For this reason, the agents of choice are usually topical and intralesional corticosteroids; however, antiperspirants, calcineurin inhibitors, tretinoin, isotretinoin, clindamycin, and contraceptives have all shown some benefit in case studies. 79 When pharmacotherapy fails, removal of the apocrine glands via liposuction-assisted curettage, electrocautery, or surgical excision is an option.…”

Section: Medical Developmentsmentioning

confidence: 99%

“…79 Both axillae were treated with a total of 50 injections of 2 units each, spaced 2 cm apart. Pruritus resolved after 15 days, and a marked reduction in the number and appearance of papules was also observed.…”

Section: Medical Developmentsmentioning

confidence: 99%

New Uses of AbobotulinumtoxinA in Aesthetics

Schlessinger¹,

Gilbert²,

Cohen³

et al. 2017

Aesthetic Surgery Journal

View full text Add to dashboard Cite

BotulinumtoxinA (BoNT-A) is now widely established for the main approved indication of reducing glabellar lines, and is also widely used off-label to improve the appearance of wrinkles and lines in other parts of the face. The number of aesthetic procedures continues to increase as the patient population becomes more diverse, in particular with increasing numbers of people of color and men. Further developments in treatment may continue to expand the audience for BoNT-A by making procedures more comfortable and by delivering a more natural, less static appearance. These may be achieved through use of combinations of BoNT-A with other aesthetic procedures, tailoring the dose of toxin to the patient’s muscle mass or by using novel injection and application techniques. Beyond amelioration of facial lines, encouraging results have been seen with the use of BoNT-A to improve the appearance of hypertrophic and keloid scars and even to prevent them. Studies have been conducted with scars in various parts of the body and further research is ongoing. Dermatological and other medical uses for BoNT-A are also active areas of research. Injections of BoNT-A have been shown to reduce signs and symptoms of acne, rosacea, and psoriasis, to reduce neuromuscular pain, and to bring about significant improvements in a number of rare diseases that are caused or exacerbated by hyperhidrosis. This paper reviews these new uses for BoNT-A, looking at the rationale for their use and discussing the results of published case studies and clinical trials. These areas have shown great promise to date, but more and larger clinical studies will be required before these treatments become a clinical reality. To this end details are also provided of clinical trials currently listed in the main clinical trials database to highlight research areas of particular interest.

show abstract

“…Dear Sir, Fox-Fordyce disease (FFD) is a rare inflammatory disorder of apocrine sweat glands, which is clinically characterized by smooth, uniform, firm, folliculocentric, yellow skin-colored papules on apocrine gland-bearing areas (1). Etiology of FFD is still unclear, but epidemiologic data support the role of hormonal component (1,2).…”

mentioning

confidence: 99%